Practical Approaches to the Use of Lenalidomide in Multiple Myeloma: A Canadian Consensus
In Canada, lenalidomide combined with dexamethasone (Len/Dex) is approved for use in relapsed or refractory multiple myeloma (RRMM). Our expert panel sought to provide an up-to-date practical guide on the use of lenalidomide in the managing RRMM within the Canadian clinical setting, including manage...
Saved in:
| Main Authors: | Donna Reece, C. Tom Kouroukis, Richard LeBlanc, Michael Sebag, Kevin Song, John Ashkenas |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Advances in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2012/621958 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01) -
Lenalidomide in the Treatment of Lymphoproliferative Disorders and Multiple Myeloma
by: Anna Marina Liberati, et al.
Published: (2013-01-01) -
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
by: Johan Lund, et al.
Published: (2018-06-01) -
Efficiency of pomalidomide therapy in patients with multiple myeloma refractory to lenalidomide
by: I. G. Rekhtina, et al.
Published: (2019-04-01) -
IMPACT OF LENALIDOMIDE MAINTENANCE DOSAGE ON SURVIVAL OUTCOMES IN MULTIPLE MYELOMA
by: Zeynep Kürüm, et al.
Published: (2025-07-01)